Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD66 | ISIN: KYG3224E1061 | Ticker-Symbol: 6HN
Tradegate
06.06.25 | 09:00
5,200 Euro
-1,89 % -0,100
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
EVEREST MEDICINES LTD Chart 1 Jahr
5-Tage-Chart
EVEREST MEDICINES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
5,2005,40006.06.
5,2005,35006.06.

Aktuelle News zur EVEREST MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEVEREST MED (01952): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - VIRTUAL MEETING ARRANGEMENTS FOR THE ANNUAL GENERAL MEETING1
DiEVEREST MED (01952): THE PRE-IPO EMPLOYEE EQUITY PLAN1
DiEVEREST MED (01952): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025-
DiEVEREST MED (01952): NOTICE OF ANNUAL GENERAL MEETING-
DiEVEREST MED (01952): (1) PROPOSED RE-ELECTION OF DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (3) PROPOSED ...-
07.05.Everest Medicines Limited: Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China229HONG KONG, May 7, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National...
► Artikel lesen
07.05.EVEREST MED (01952): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FULL APPROVAL OF NEFECON BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THE TREATMENT ...3
EVEREST MEDICINES Aktie jetzt für 0€ handeln
25.04.EVEREST MED-B (01952): REMOVAL OF STOCK MARKER "B"1
24.04.EVEREST MED-B (01952): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
24.04.EVEREST MED-B (01952): 2024 ANNUAL REPORT-
22.04.Everest Medicines Limited: Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange325SHANGHAI, CHINA, Apr 22, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...
► Artikel lesen
22.04.EVEREST MED-B (01952): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES-
15.04.EVEREST MED-B (01952): (1) CHANGE OF COMPANY SECRETARY (2) CLARIFICATION REGARDING THE PRE-IPO ESOP7
01.04.EVEREST MED-B (01952): (1) GRANT OF OPTIONS (2) GRANT OF AWARDS (3) NON-EXEMPT CONNECTED TRANSACTIONS - PROPOSED AWARD GRANTS TO CONNECTED PERSONS1
26.03.Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024110SHANGHAI, March 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery...
► Artikel lesen
25.03.EVEREST MED-B (01952): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20241
25.03.EVEREST MED-B (01952): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE-
25.03.Everest Medicines drives growth with AI-powered mRNA pipeline1
24.03.Everest Medicines' EVM14 TAA Cancer Vaccine Gets FDA Clearance To Advance Into Clinical Testing1
24.03.Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14129EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1